Group 1 - The MSCI China Healthcare Index has increased by 11.8% year-to-date, outperforming the MSCI China Index which rose by 9.1% [1] - The pharmaceutical industry has seen significant growth, primarily due to the valuation correction that occurred in the fourth quarter of last year, leading to strong allocation interest from institutional investors at the beginning of the year [1] - The trend of innovative drugs going overseas is expected to continue until 2026, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 2 - The report recommends buying shares in companies such as 3SBio, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.08% as of January 13, 2026, driven by significant gains in stocks such as Rongchang Bio (+9.38%), WuXi AppTec (+7.67%), and Tigermed (+7.66) [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing AI in drug development, AI-enabled pharmaceutical supply chains, surgical robots, and intelligent diagnostic systems as key development areas, with a goal to cultivate 2-3 ecosystem-leading enterprises by 2027 [1] - The integration of AI and healthcare is seen as a clear trend, with hardware companies represented by brain-computer interfaces and surgical robots expected to benefit from policy support and technological advancements [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, accounting for a total of 71.36% of the index [2] - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest closely tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research and development, as well as services for pharmaceutical companies [2] - Investors without stock accounts can access the opportunities in the Hong Kong innovative drug industry through the Hong Kong Stock Connect Innovative Drug ETF linked fund [2]

Group 1 - The core viewpoint of the news highlights the positive performance of the innovative drug sector in the stock market, with significant gains in individual stocks and ETFs [1][3] - The new national medical insurance drug catalog will be implemented on January 1, 2026, adding 114 new drugs, including 50 Class 1 new drugs, marking a record high in both quantity and proportion [2] - The commercial insurance catalog will include 19 high-value innovative drugs, addressing accessibility issues for high-value innovative treatments [2] Group 2 - The collaboration between domestic innovative drug companies and multinational corporations continues, with 49 outbound transactions totaling over $39 billion since October last year [3] - The market is entering a peak season for business development (BD) and data disclosures, coinciding with the JPM conference and the upcoming annual report cycle [3] - The Hong Kong Stock Connect Innovative Drug ETF (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.95% of the total weight [3]

（文章来源：每日经济新闻） 每经AI快讯，中国生物制药(01177.HK)一度涨超4%，截至发稿涨3.5%，报7.09港元，成交额4.31亿港 元。 ...

中国生物制药（01177）盘中涨超4%，截至发稿，股价上涨3.50%，现报7.09港元，成交额4.39亿港元。 基于销售数据，美银证券微调其2026及2027年收入预测，目标价从9.4港元下调至8.3港元。此外，石药 集团因重点药品销售低迷，被维持"跑输大市"评级。 来源：新浪港股 报告显示，医院渠道销售额按年转降3.3%，零售渠道基本持平。中国生物制药产品表现分化，部分核 心产品销售额增长，但另一些显著下滑。 近日，美银证券发布报告指出，10月中国内地医药行业药品销售额按年下降3%，增速较9月大幅回落， 并重申对中国生物制药的"买入"评级。 ...

Core Viewpoint - China Biologic Products (01177) has seen a stock increase of over 4%, currently trading at 7.09 HKD with a transaction volume of 431 million HKD, as reported by UBS [1] Group 1: Business Development - The management of China Biologic Products indicated that more time is needed to finalize the guidance for its out-licensing (BD) business for this year [1] - Key data results expected this year include Phase I clinical data for TQB3702 in blood cancer, Phase II clinical data for TQA3334, and Phase III clinical data for lanifibranor targeting metabolic-associated fatty liver disease [1] Group 2: Market Outlook - The management is optimistic about the inclusion prospects of VIIa in the 2025 National Medical Insurance Drug List negotiations, as only three companies are selected for inclusion [1] - Penpulimab has successfully entered the medical insurance list for the first time, while anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction [1] - Yilishu benefits from an expanded reimbursement scope [1] Group 3: Product Information - The VIIa product is the recombinant human coagulation factor VIIa N01 (brand name: Anqixin) developed by China Biologic Products' subsidiary, which received NMPA approval for market entry on July 3, 2025 [1] - This product is the first domestically produced recombinant human coagulation factor VIIa biological product, breaking the long-standing monopoly of imported products, improving drug accessibility for hemophilia patients, and reducing treatment costs [1]

Core Viewpoint - China Biologic Products (01177) has seen a stock increase of over 4%, currently trading at 7.09 HKD with a transaction volume of 431 million HKD. UBS reports that the management requires more time to finalize the guidance for the business development of external authorization (BD) this year [1] Group 1: Clinical Data and Product Development - The company is expected to announce clinical data results this year, including Phase I clinical data for TQB3702 in blood cancer, Phase II clinical data for TQA3334, and Phase III clinical data for lanifibranor targeting metabolic-associated fatty liver disease [1] - Management is optimistic about the inclusion prospects of VIIa in the 2025 National Medical Insurance Drug List negotiations, as only three companies have been selected for inclusion [1] Group 2: Recent Approvals and Market Impact - Penpulimab has successfully entered the medical insurance catalog for the first time, while anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction [1] - Yilishu benefits from an expanded reimbursement scope, enhancing its market accessibility [1] Group 3: Product Significance - The VIIa product, developed by the company's subsidiary, is the first domestically produced recombinant human coagulation factor VIIa (brand name: Anqixin), which received NMPA approval on July 3, 2025 [1] - This product breaks the long-standing monopoly of imported products, improving medication accessibility for hemophilia patients and reducing treatment costs [1]

Core Viewpoint - The Chinese innovative drug sector is experiencing significant growth, highlighted by the recent clinical advancements and strategic partnerships, indicating a positive long-term trend in the industry. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (南方, 159297) rose by 2.98%, with a turnover of 53.79 million yuan and a turnover rate of 3.2% [1] - Key stocks in the index, such as Rongchang Biopharmaceuticals, Sihuan Pharmaceutical, and Boan Biotechnology, saw substantial increases of 9.38%, 7.38%, and 6.71% respectively [1] Group 2: Clinical Developments - The GLP-1 class drug, Masitide, developed in China, achieved a milestone with two pivotal Phase III clinical studies published in the prestigious journal Nature on December 18, 2025, showcasing China's drug development capabilities [1] Group 3: Strategic Partnerships - Rongchang Biopharmaceuticals announced an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with tiered royalties on net sales outside Greater China [1] Group 4: Industry Trends - Guosen Securities noted the explosive growth in business development (BD) transactions within the Chinese innovative drug industry, emphasizing that for many domestic innovative drugs, external licensing is just the starting point for global development [2] - The Hong Kong pharmaceutical sector has shown strong performance, particularly in the biotech field, reflecting heightened market interest in innovative drugs [2] Group 5: AI Integration - Eight departments jointly issued implementation opinions on "AI + Manufacturing," focusing on AI in drug development and medical supply chains, with a goal to cultivate 2-3 leading ecological enterprises by 2027 [2] - Century Securities highlighted the significant potential of AI in enhancing pharmaceutical manufacturing, particularly in drug discovery and intelligent diagnostics, which is expected to receive ongoing policy support and capital attention [2] Group 6: Index Composition - The index tracking the Hong Kong Stock Connect Innovative Drug sector includes major companies such as CSPC Pharmaceutical Group, BeiGene, and Innovent Biologics among its top ten weighted stocks [3]

Investment Rating - The industry investment rating is "Buy" for companies such as 三生制药 (1530 HK), 固生堂 (2273 HK), 药明合联 (2268 HK), and 中国生物制药 (1177 HK) [3][4][32]. Core Insights - The MSCI China Healthcare Index has increased by 11.8% since the beginning of 2026, outperforming the MSCI China Index which rose by 9.1%. The pharmaceutical sector has seen significant growth due to strong institutional investor interest at the start of the year following a valuation correction in Q4 of the previous year [2]. - The trend of innovative drugs going overseas is expected to continue in the long term, with a focus on the clinical progress and data validation of pipelines that have already gone abroad [2]. - The domestic innovative drug market is still relatively small, with an estimated market size of 300-400 billion RMB, of which domestic innovative drugs account for about 1/3, or 100-130 billion RMB. If the proportion of patented drugs in China reaches 66% like the global average, the market size could potentially reach around 760 billion RMB [6]. Summary by Sections Company Recommendations - Recommended companies for investment include 三生制药 (1530 HK), 固生堂 (2273 HK), 药明合联 (2268 HK), and 中国生物制药 (1177 HK) [3][4]. Market Trends - The market for domestic innovative drugs is characterized by high demand due to aging populations, weak pricing from insurance negotiations, strong competition, and short product life cycles. The global pharmaceutical market is projected to reach 1.74 trillion USD in 2024, with China's market size at 166 billion USD, representing only 9.5% of the global market [6]. - The potential market size for domestic innovative drugs going abroad could reach 110 billion USD, nearly 800 billion RMB, if one-third of the global patented drug market is sourced from China [6]. Clinical Development and Financials - In 2025, the total transaction amount for BD (business development) licensing for Chinese innovative drugs is expected to reach 135.65 billion USD, a year-on-year increase of 161%, with 70 million USD in upfront payments [6]. - Basic medical insurance expenditure showed a slight recovery in 2025, with cumulative spending growth of 0.5% and income growth of 2.9%, indicating a shift in the growth catalyst from insurance to out-of-pocket and commercial insurance [6].

Core Insights - The article discusses the upcoming 44th J.P. Morgan Global Healthcare Conference, focusing on the evolving landscape of the healthcare industry and investment opportunities within various sectors [4][28]. - It highlights the shift in investment focus from conceptual discussions to tangible clinical and commercialization pathways, particularly in biotechnology and biopharmaceuticals [6][24]. Group 1: Conference Overview - The conference will feature approximately 530 participating entities, categorized into six main sectors, with biotechnology and biopharmaceuticals representing 44.1% of the total [6]. - The event aims to address key investment questions regarding which sectors are transitioning from theoretical discussions to practical applications and which companies are likely to achieve cross-cycle premium valuations [4]. Group 2: Sector Analysis - **Biotechnology Sector**: Comprises 24.1% of participants, focusing on clinical and regulatory milestones. Companies like BridgeBio and Sarepta are highlighted for their advancements in genetic therapies [13]. - **Biopharmaceutical Sector**: Accounts for 20.0% of participants, with a focus on stable cash flows and research efficiency. Companies such as AbbVie and Amgen are noted for their strong market positions and innovative pipelines [14][15]. - **Medical Devices Sector**: Represents 7.6% of participants, emphasizing the importance of clinical integration and operational efficiency in device adoption. Companies like Intuitive Surgical and Dexcom are recognized for their impactful innovations [17]. - **Healthcare Services and Payments Sector**: Also at 7.6%, this sector faces challenges due to regulatory changes and market dynamics. The focus is on understanding profit structures and cost management [18]. - **Digital Health Sector**: Comprises 3.7% of participants, with companies like Veeva and Teladoc addressing efficiency and cost control in healthcare delivery [19]. - **Diagnostics and Precision Medicine Sector**: Focuses on the integration of diagnostic tools into clinical pathways, with companies like Illumina and Guardant Health leading the way [20][21]. Group 3: Trends and Opportunities - The article notes a significant shift in the role of Chinese CXO companies in the global pharmaceutical innovation ecosystem, moving from cost-driven outsourcing to integral participants in drug development [11]. - The conference reflects a consensus on the need for clear pricing strategies and the importance of clinical, payment, and commercialization pathways in determining company valuations [28][30]. - Chinese pharmaceutical companies are transitioning from domestic validation of technologies to proving their global indispensability, with a focus on international clinical trial efficiency and global registration pathways [22][24][26].